ReCode Therapeutics Announces Participation in Upcoming October Investor Conferences

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that Company leadership will participate in three upcoming virtual investor conferences in October:

• Chardan 5^th Annual Genetic Medicines Conference
  Format: Presentation
  Date: Monday, October 4, 2021
  Time: 1:30 p.m. ET
  
  Format: Panel titled “RNA: RNA-based Targeted Delivery Approaches”
  Date: Tuesday, October 5, 2021
  Time: 3:00 p.m. ET

• Piper Sandler Lung Day
  Format: Fireside Chat
  Date: Friday, October 15, 2021
  Time: 11:30 a.m. ET

• Needham Virtual Biotech Private Company 1x1 Forum
  Format: 1x1 Meetings
  Date: Tuesday, October 19 – Wednesday, October 20, 2021

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.